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In a bid to reduce the morbidity and mortality associated with coronary artery disease, statin therapy has become
a cornerstone treatment for patients with dyslipideamia. Statins, or HMG-CoA reductase inhibitors, are effective in
blocking hepatic synthesis of cholesterol and are generally regarded as safe. Although rare, severe adverse side
effects such as rhabdomyolysis have been reported, however, the more common complaint from patients is that
related to myopathy. There is also mounting evidence that exercise may exacerbate these side effects, however the
mechanisms are yet to be fully defined and there is controversy regarding the role that inflammation may play in
the myopathy. This paper reports a patients experience during 6 months of simvastatin therapy and provides some
insight into the white cell count (inflammation) following two bouts of moderate intensity exercise before and
during statin therapy. It also highlights the need for rehabilitation practitioners to be aware of the adverse effects
of statins in exercising patients.
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Introduction
Reducing high cholesterol levels through pharmacother-
apy is a key goal for patients with dyslipedemia. Despite
the controversy surrounding statins they remain one of
the most widely prescribed groups of lipid-lowering
drugs simply because of their effectiveness [1]. Serious
adverse side effects are rare, however, myopathy symp-
toms including fatigue, weakness, cramps and muscle
pain are commonly reported by patients [2]. These symp-
toms may be exacerbated in patients who exercise [2]
and be prevalent in as many as 75% of athletes who take
the drug [3]. The underlying mechanism(s) responsible
for the statin-induced myopathy is unclear, however
there is evidence that statins may upregulate muscle cell
apoptosis, inflammation and protein catabolism in
response to eccentric exercise [4]. Whether or not
6 months of statin therapy induces skeletal muscle
related changes such that indirect markers of muscle
damage are exacerbated following ‘normal’ sessions that
induce moderate muscle soreness, is yet to be established.
Indeed some will argue that there are currently very few
studies implicating inflammation as a factor that may
exacerbate statin therapy induced complications [5].
Patient background
A 34 year old male (weight 63 kg; BMI 21.8 kg/m
2)p r e -
sented to his general practitioner (GP) for a routine med-
ical check-up. The patient, a non-smoker, had no
known/diagnosed chronic disease, injury or infection,
was on no medication and was generally in good health.
As a junior athlete the patient had participated competi-
tively in endurance activities (cross-country, athletics, tri/
duathlon) at provincial and national level, and for the last
13 years his motivation to engage in regular physical
activity was driven by the health belief model. On aver-
age, his training over the last few years included 3 road
running sessions per week (2 × 30-40 min during the
week and 1 × 60-100 min on the weekend). These ses-
sions were usually completed at moderate intensity with
the odd session (1 out of every 4) being conducted at
high intensity. He has a family history of cardiovascular
disease (hypertension and dyslipidemia). 24 h prior to the
GP consult he had completed a training run of 1 h
4 2m i n( F i g u r e1 ) .O nr e c e i v i n gt h ep a t h o l o g yr e s u l t s
from the routine medical examination he was prescribed
10 mg simvastatin and advised to reassess the lipoprotein
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this case study was granted from the institutions Faculty
of Science & Agriculture Ethics Committee and the
research complied with the Declaration of Helsinki.
Three weeks after initiating the treatment the patient
participated in a 21.1 km road race. He exerted himself
harder than usual on an undulating course (finishing time
1 h 40 min). It was following this event that the he started
to report muscle aches during rest. The event seemed to
‘trigger’ the symptoms of myopathy and the patient also
reported that it took an “unusually long time to recover”.
The patient subsequently reported heavy legs during all
training sessions regardless of the intensity and continued
to experience myalgia for approximately 3 months. The
intermittent discomfort at rest, together with the sensation
of heavy legs whilst training, was pronounced enough for
the patient to query these symptoms with his GP who
recommended changing from simvastatin to a different
statin. For the purposes of this case study the patient
remained on the simvastatin. Importantly the patients pre-
statin exercise regimen remained the same as for the dura-
tion of the 6 months before the second blood draw. Once
again he completed the same route and distance in a com-
p a r a b l et i m e( 1h4 3m i n4 0s )2 4hp r i o rt ot h es e c o n d
blood draw. The pre-exercise meal and fluid ingestion
during both runs was the same.
Discussion
The effectiveness of the statin therapy in reducing choles-
terol levels in this patient is evident in Table 1. The
patient did not make any modifications to his diet during
the 6 months. Although still not within the target range,
total cholesterol decreased by 14%, triglycerides and
LDL’s decreased by 18% and 14% respectively. White cell
count was elevated after run 2 by 8%, with a 75% eleva-
tion in lymphocytes and a 1200% elevation in eosinophils.
More modest elevations were observed for neutrophils
following the second run (1.6%). The increased white cell
count following the statin therapy may suggest that
inflammation was up-regulated following run 2. White
cell counts are commonly used to identify or measure
exercise-induced inflammatory responses [6]. Recently
Boutibir et al. [7] showed that statin therapy in rats sig-
nificantly reduces exercise capacity and that the more
pronounced reactive oxygen species (ROS) production
that they observed during the exercise may be responsi-
ble for the finding. Similarly, another recent study by
Kwak et al. [8] has shown that simvastatin increases oxi-
dative stress and atrophy in human muscle cells. Based
on these findings and those of the current case study it
would seem reasonable to suggest that statin therapy
may induce changes in human muscle such that ROS
production during exercise increases with a concomitant
increase in inflammation. Statins exhibit potent anti-
inflammatory properties [9]. What then may be the rea-
son for the observed increase in WBC levels following
exercise in this patient? Creatine kinase, another indirect
marker of muscle damage is significantly elevated in sta-
tin users following exercise when compared to non-statin
users [10]. Urso et al. [11] have hypothesized that statin
therapy may negatively affect the stability of skeletal mus-
cle cell membranes. This may in part explain why CK is
elevated following exercise, particularly strenuous or
unaccustomed exercise. The more pronounced muscle
damage may up-regulate inflammation which in turn
could account for the longer recovery time that exercis-
ing patients experience.
The patient did report the occurrence and severity of
aching muscles and heavy legs to subside after 3 months
but these symptoms did not resolve completely. In addi-
tion the patient reported that the myopathy during, and
recovery time from flu was gauged to be worse and
longer than normal. Despite myopathies being the most
commonly reported side effect of statin therapy the
patient was not informed of the potential side effects of
the drug until he consulted his GP after 3 months of
therapy. Clinicians and rehabilitation practitioners should
be aware of the prevalence and potential negative effects
that statin therapy has on patients (even in low doses)
and in particular on those patients that regularly engage
in physical activity. It is arguable that this is even more
pertinent for patients who were previously sedentary and
then begin exercising as part of their chronic disease
rehabilitation plan. The paradox which exists for these
patients is that physical activity which is supposed to
improve functionality and quality of life may actually
exacerbate the myopathy if they are taking statins. This
makes adherence to physical rehabilitation programmes a
challenge. There are also practical implications for pro-
gramme design by rehabilitation practitioners. Longer
rest periods between training sessions and/or alternating
between activities that stress different musculature and
metabolic pathways may be required especially during
the first 10-12 weeks of exercising. To date there is very
little information available on inflammatory responses to
exercise before and following long term treatment with
Figure 1 Case Study Design.
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eration or leukocyte function prior to and after statin
therapy with and without exercise exposure would pro-
vide greater insight into the association between inflam-
mation, exercise and myopathy. Unfortunately, for this
case study, the patients routine pathology tests did not
include such measures, however the results do tend to
suggest that quantitatively there is a change in the
inflammatory response, and in the absence of alterations
to diet, physical activity patterns or other known pathol-
ogy it would seem reasonable to suggest that the statin
treatment is linked to this observation.
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Table 1 Pre and 6 month post statin therapy lipoprotein and white blood cell concentrations
Pre-statin therapy
♦ 6 months post-statin therapy
♦ Normative range
Cholesterol (total) 7.1 6.1 2.8 - 4.9 mmol/l
Triglycerides 2.2 1.8 0.5 - 1.6 mmol/l
HDL Cholesterol 1.5 1.5 1.0 - 1.6 mmol/l
LDL Cholesterol 4.9 4.2 1.6 - 2.9 mmol/l
White cell count 5.65 6.10 3.92 - 9.88 10
^9/l
Neutrophils 3.03 3.08 2.00 - 7.50 10
^9/l
Lymphocytes 1.32 2.32 1.00 - 4.00 10
^9/l
Monocytes 0.37 0.37 0.18 - 0.80 10
^9/l
Basophils 0.09 0.05 0.00 - 0.20 10
^9/l
Eosinophils 0.02 0.27 0.00 - 0.45 10
^9/l
ESR 2 2 2 - 2.8 mm/hr
Creatinine 93 95 64 - 104 umol/l
♦ Fasting samples obtained 24 h after a 20 km training run; HDL = high density lipoproteins; LDL = low density lipoproteins; ESR = erythrocyte sedimentation
rate
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